Global Custom Market Research Reports Provider Company

phone

Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) – Pipeline Review, H1 2018

  • Published Date: 06 Mar 2018
  • Number of Pages: 48
  • Category: Pharmaceuticals
  • Country: Global
Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) Pipeline Review, H1 2018

Summary

According to the recently published report Glucose Dependent Insulinotropic Receptor Pipeline Review, H1 2018; Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) pipeline Target constitutes close to 15 molecules. Out of which approximately 14 molecules are developed by companies and remaining by the universities/institutes.

Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) G protein-coupled receptor 119 also known as GPR119 is a G protein-coupled receptor that is encoded by the GPR119 gene. GPR119 is expressed at high concentrations in the pancreas and gastrointestinal tract. GPR119 regulates incretin and insulin hormone secretion. Activation of GPR119 receptor causes a reduction in food intake and weight gain. This target is a potential drug target in treatments for obesity and diabetes.

The report Glucose Dependent Insulinotropic Receptor Pipeline Review, H1 2018 outlays comprehensive information on the Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) targeted therapeutics development with respective active and dormant or discontinued projects.
Currently, The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 10 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Metabolic Disorders, Respiratory and Undisclosed which include indications Type 2 Diabetes, Obesity, Chronic Obstructive Pulmonary Disease (COPD) and Unspecified.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119)
- The report reviews Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) targeted therapeutics and enlists all their major and minor projects
- The report assesses Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
Publisher Name : Global Markets Direct
Introduction
Global Markets Direct Report Coverage
Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) Overview
Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) Companies Involved in Therapeutics Development
Amgen Inc
Arena Pharmaceuticals Inc
CymaBay Therapeutics Inc
Dong-A Socio Holdings Co Ltd
GlaxoSmithKline Plc
Hyundai Pharmaceutical Co Ltd
Kowa Co Ltd
Merck & Co Inc
Novartis AG
Taisho Pharmaceutical Holdings Co Ltd
Takeda Pharmaceutical Co Ltd
Yuhan Corp
Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) Drug Profiles
DA-1241 Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GSK-2041706 Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HD-0471042 Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HOB-047 Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MBX-2982 Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SCO-094 Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Agonize GPR119 for Type 2 Diabetes Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Agonize GPR119 for Type 2 Diabetes Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Agonize GPR119 Receptor for Unspecified Indication Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Agonize GRP119 for Type 2 Diabetes and Obesity Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize GPR119 for Type 2 Diabetes Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize GPR119 for Type 2 Diabetes Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize GPR119 for Type 2 Diabetes Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize GPR119 Receptor for Type 2 Diabetes Drug Profile
Product Description
Mechanism Of Action
R&D Progress
YH-18420 Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) Dormant Products
Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) Discontinued Products
Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) Product Development Milestones
Featured News & Press Releases
Nov 05, 2009: Metabolex Closes $8.6 Million Financing Round
Nov 12, 2008: Metabolex Announces Positive Results From Phase 1a Clinical Trial Of MBX-2982
Mar 26, 2008: Metabolex, Inc. Initiates Phase 1 Trial Of MBX-2982
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

List of Tables
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Indication, H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Number of Products under Investigation by Universities/Institutes, H1 2018
Products under Investigation by Universities/Institutes, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Pipeline by Amgen Inc, H1 2018
Pipeline by Arena Pharmaceuticals Inc, H1 2018
Pipeline by CymaBay Therapeutics Inc, H1 2018
Pipeline by Dong-A Socio Holdings Co Ltd, H1 2018
Pipeline by GlaxoSmithKline Plc, H1 2018
Pipeline by Hyundai Pharmaceutical Co Ltd, H1 2018
Pipeline by Kowa Co Ltd, H1 2018
Pipeline by Merck & Co Inc, H1 2018
Pipeline by Novartis AG, H1 2018
Pipeline by Taisho Pharmaceutical Holdings Co Ltd, H1 2018
Pipeline by Takeda Pharmaceutical Co Ltd, H1 2018
Pipeline by Yuhan Corp, H1 2018
Dormant Products, H1 2018
Dormant Products, H1 2018 (Contd..1), H1 2018
Discontinued Products, H1 2018

List Of Figures

List of Figures
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Top 10 Indications, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018

Proteinase Activated Receptor 2 (PAR2 or Coagulation Factor II Receptor Like 1 or G Protein Coupled Receptor 11 or Thrombin Receptor Like 1 or GPR11 or F2RL1) - Pipeline Review,

View Report

Melanin Concentrating Hormone Receptor 1 (G Protein Coupled Receptor 24 or MCH 1R or Somatostatin Receptor Like Protein or GPR24 or SLC1 or MCHR1) - Pipeline Review, H2 2018 Melanin Concentrating

View Report

Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) - Pipeline Review, H2 2018 Histamine H4 Receptor (AXOR35 or G

View Report
There is no reviews available for this report

Select License Type

Delivery Details

Delivery Details : Electronic files (PDF) of market research reports will dispatched within 12 to 24 hours. (Mon-Fri IST)

Customized Report

If a particular report is not as per your requirement you can ‎choose "Customized Report". To visit click on -

Custom Research Reports